Am J Transplant, Volume 16, Suppl 3 Archives - Page 155 of 180 - ATC Abstracts

2016 American Transplant Congress
Give One and Done? Evaluating a Change in Surgical Prophylaxis in Kidney Transplant Recipients.
K. Bliven, C. Truax, K. Snow, N. Kenyon, A. Carlson, S. Yeager, L. Smith.
Pharmacy, University of Utah Hospital and Clinics, Salt Lake City, UT.
Surgical-site infections (SSIs) occur in up to 11% of kidney transplant (txp) patients (pts). There is no consensus on the optimal peri-op prophylaxis regimen for…
2016 American Transplant Congress
Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.
A. El-Agroudy,¹ A. Taher,² A. Alaradi,² B. Alhayki,² S. Gareeb,² E. Farid.²
¹Internal Medicine, College of Medicine, Arabian Gulf University, Manama, Bahrain; ²Nephrology, Salmaniya Medical Complex, Manama, Bahrain.
Background: Mycophenolate mofetil (MMF) is a highly effective immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by…
2016 American Transplant Congress
Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1 , Hepatitis C Infection Post Liver Transplant.
D. Jones,¹ S. Baggett,¹ M. Shoreibah,² O. Massoud.²
¹Department of Pharmacy, UAB Hospital, Birmingham, AL; ²Department of Gastroenterology, UAB Hospital, Birmingham, AL.
Background. With the development of direct-acting antivirals, the treatment of Hepatitis C Virus (HCV) has become a rapidly changing area of medical practice. Data on…
2016 American Transplant Congress
Potential Biomarkers and Treatment for BK Virus Associated Nephropathy.
M. Borkar,¹ V. Srivastava,² R. Cunnington,¹ T. Sharma,¹ L. Tibbles.¹
¹Faculty of Mediicne, University of Calgary, Calgary, AB, Canada; ²CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.
Background: BK polyomavirus assoiciated nephropathy (BKVAN) is one of the major complications in renal transplants, and is associated with significant fibrosis It is important to…
2016 American Transplant Congress
Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).
M. Bories,¹ S. Varnous,² C. Lefaucheur,³ P. Rouvier,² R. Guillemain,¹ P. Bruneval,¹ J. Duong Van Huyen,⁴ A. Loupy.⁴
¹European Georges Pompidou Hospital, Paris, France; ²La Pitié Salpêtrière Hospital, Paris, France; ³Saint-Louis Hospital, Paris, France; ⁴Necker Hospital, Paris, France.
Introduction The role of circulating DSA in addition to traditional cardiovascular risk factors, in the development of accelerated CAV have not been demonstrated. We investigated…
2016 American Transplant Congress
Intestinal Retransplantation in Children: Single Center Experience.
N. Celik,¹ F. Vyas,¹ G. Bond,¹ K. Soltys,¹ J. Rudolph,² R. Sindhi,¹ G. Mazariegos.¹
¹Hillman Center for Pediatric Transplantation, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Intestinal Care and Rehabilitation Center, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
Aim: To analyze the patient and graft characteristics and improvement in patient outcomes for intestinal retransplantation (Re-ITx) in the era of induction immunosuppression with the…
2016 American Transplant Congress
Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas.
A. Sang, G. Ivison, C. Esquivel, S. Krams, O. Martinez.
Division of Abdominal Transplantation, Stanford School of Medicine, Stanford, CA.
Epstein-Barr virus (EBV) B cell lymphomas in post-transplant lymphoproliferative disorder (PTLD) is a major problem in organ transplantation. Reduction of immunosuppression sometimes result in tumor…
2016 American Transplant Congress
Assessing the Impact of the Share35 Liver Allocation Policy: Survival Outcomes Among Liver Re-Transplant Recipients.
J. Ortiz,¹ N. Koizumi,² C. Kwon,² Y. Zhang,² C. Ortiz.³
¹Department of Surgery, University of Toledo, Toledo, OH; ²George Mason University, Fairfax, VA; ³Bucknell University, Lewisburg, PA.
Liver retransplantation (reLTx) is the only treatment option for those who experienced graft loss after primary liver transplantation (LTx). Yet, in an era of increasing…
2016 American Transplant Congress
Immune Response to BK Virus in Renal Transplant Recipients.
D. DeWolfe,¹ J. Gandhi,¹ M. Mackenzie,¹ T. Broge,¹ E. Bord,¹ D. Mandelbrot,¹ R. Viscidi,² F. Cardarelli,¹ M. Pavlakis,¹ C. Tan.¹
¹Medicine, Beth Israel Deaconess Medical Center, Boston, MA; ²Pediatrics, Johns Hopkins Medical Center, Baltimore, MD.
Background: The adaptive immune characteristics associated with BK Virus (BKV) infection and control remain incompletely described. In this study we further elucidate the immune response…
2016 American Transplant Congress
AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.
J. O'Leary,¹ A. Philippe,² H. Heidecke,² R. Freeman,¹ L. Jennings,¹ R. Catar,² G. Klintmalm,¹ D. Dragun.²
¹Baylor Simmons Transplant Insttute, Baylor University Medical Center, Dallas, TX; ²Internal Medicine, Charite, Berlin, Germany.
Angiotensin II Type-1 Receptor (AT1R) antibodies have been associated with pulmonary hypertension, renal allograft loss, and fibrosis progression in liver allograft recipients especially if combined…